The FDA has given Siesta Medical expanded clearance for the company's Encore tongue suspension device. The company, which is headquartered in Los Gatos, Calif., can now market the device for multiple suspension loop applications and as a fully adjustable system after implantation in patients with obstructive sleep apnea. "Siesta believes the Encore system is a ... cost effective surgical option for treating OSA patients unable to comply with CPAP use,” said company President and CEO Peter Martin.
FDA widens clearance for Siesta's tongue suspension device
SmartBrief Job Listings for Health Care